Aurinia Pharmaceuticals

Update in progress

AUPH (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune diseases with high unmet medical needs, serving patients in the United States and Japan. Its approved product is LUPKYNIS (voclosporin), an oral medicine for adults with active lupus nephritis. The company is also developing aritinercept, a dual inhibitor of B cell-activating factor and APRIL, for potential autoimmune indications. Founded in 1993, it is headquartered in Edmonton, Canada.

Company score

Sentiment: 0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive